ClinicalTrials.Veeva

Menu

Impact of Diet on the Microbiome-Immune-Brain Axis in Parkinson's Disease

U

University of Kiel

Status

Not yet enrolling

Conditions

Parkinson Disease

Treatments

Behavioral: 8 week predominantly plant-based New Nordic LPF-diet program
Behavioral: maintenance of the predominantly plant-based New Nordic LPF-diet

Study type

Interventional

Funder types

Other

Identifiers

NCT06463769
CRC1697-C04

Details and patient eligibility

About

Habitual adherence to a predominantly plant-based diet, rich in low-processed food (LPF) has been associated with a reduced risk for development and slower progression of Parkinson's Disease (PD). This could be due to neuroprotective effects by modulation of the gut microbiota and decreased neuronal and metabolic inflammation. So far, the effect of a predominantly plant-based LPF-diet on the microbiome-immune-brain axis in patients with PD remains unknown. In addition, the influence of dietetic measures on the gut microbiome is variable and may depend on (long-term) adherence as well as on PD-specific factors and lifestyle.

The investigators hypothesize that compared to an average German diet, the predominantly plant-based New Nordic LPF-diet, as a culturally adapted diet, which is rich in fermentable fiber and phytochemicals, will have beneficial effects on the gut microbiome of patients with PD by increasing the abundance of short-chain fatty acid (SCFA)-producing bacteria (primary outcome) and will improve gut motility, metabolic resilience, and inflammation (secondary outcomes). Furthermore, the investigators postulate that a patient-centered dietary intervention program, including a multifaceted patient education and supported by a web-application, will lead to high adherence as a key determinant of long-term changes in the gut microbiome. This dietary intervention will be accepted by patients as a low-threshold treatment that balances personal benefits, therapeutic barriers and ethical concerns of early risk disclosure in PD.

Full description

In a pilot-intervention study, our project will:

  • develop a practical, low-threshold diet intervention for patients with prodromal and clinical PD. Adherence will be promoted (i) by a patient-oriented approach, (ii) by implementation of the predominantly plant-based New Nordic LPF-diet that is scientifically-based, culturally adapted, sustainable and culinary and (iii) by an innovative web-application.
  • investigate the acute effects of the predominantly plant-based New Nordic LPF -diet on the microbiome (abundance of SCFA-producing bacteria), gastrointestinal motility, inflammation as well as metabolic and Parkinson-specific clinical outcomes in individuals with prodromal and clinical PD.
  • investigate potential determinants of long-term changes in the gut microbiome (e.g. dietary adherence, gastrointestinal motility, meal timing and frequency), and factors associated with a high adherence (e.g. acceptance of diet as therapeutic intervention in the prodromal phase, health-related quality of life).

The patient-centered intervention program will be tailored to individual needs and preferences of individuals with prodromal and clinical PD. It will be designed to impart knowledge (e.g. on sustainability and health effects) and food literacy (e.g. food merchandize and culinary skills) in group meetings and culinary medicine workshops. Recipe suggestions and shopping guides will consider individual abilities and needs and a web-application is used for information, increasing self-efficacy, motivation, and monitoring. To ensure an easy integration of the diet into everyday life, partners will be included in the program, if applicable. Moreover, cultural preferences as well as financial resources will be considered. Regular feedback using statistics on nutrient intake and overall progress will be implemented to encourage adherence.

Enrollment

75 estimated patients

Sex

All

Ages

50 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • patients with probable prodromal PD (according to predefined criteria)
  • patients with clinical PD with slight to moderate disease severity (Hoehn & Yahr 1-2.5)
  • habitual Western Diet (≥30% of energy intake from ultra-processed food)

Exclusion criteria

  • current adherence to a plant-based diet
  • food allergies or intolerances
  • significant diseases of the gastrointestinal system (e.g. celiac disease) or central nervous system, diabetes mellitus
  • underweight (BMI <18.5 kg/m2)
  • active smoking
  • expected changes in medication or antibiotic treatment during the intervention

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

75 participants in 3 patient groups

Patients with prodromal PD on New Nordic LPF-diet (intervention)
Experimental group
Description:
Patients with prodromal PD will take part in an 8-week patient-centered intervention program on a predominantly plant-based New Nordic LPF-Diet.
Treatment:
Behavioral: maintenance of the predominantly plant-based New Nordic LPF-diet
Behavioral: 8 week predominantly plant-based New Nordic LPF-diet program
Patients with clinical PD on New Nordic LPF-diet (intervention)
Experimental group
Description:
Patients with clinical PD will take part in an 8-week patient-centered intervention program on a predominantly plant-based New Nordic LPF-Diet. Patients with clinical PD will be randomized to intervention or control group.
Treatment:
Behavioral: maintenance of the predominantly plant-based New Nordic LPF-diet
Behavioral: 8 week predominantly plant-based New Nordic LPF-diet program
Patients with clinical PD receiving standard of care (control)
No Intervention group
Description:
Patients with clinical PD will receive standard of care information on a healthy diet and serve as control. Patients with clinical PD will be randomized to intervention or control group.

Trial contacts and locations

2

Loading...

Central trial contact

Eva Schäffer, MD; Anja Bosy-Westphal, PhD, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems